Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Friday, March 27th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.06) per share for the year. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.08).

A number of other analysts have also recently weighed in on the company. Wall Street Zen cut Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price objective for the company. Finally, Guggenheim reaffirmed a “buy” rating and issued a $6.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $5.17.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $2.10 on Monday. The company has a market cap of $148.95 million, a P/E ratio of -1.11 and a beta of 1.71. The business has a 50 day moving average of $2.57 and a two-hundred day moving average of $1.95. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $3.95.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its stake in Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after buying an additional 8,236 shares in the last quarter. Invesco Ltd. grew its holdings in Zentalis Pharmaceuticals by 8.6% during the fourth quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock worth $255,000 after acquiring an additional 14,961 shares during the period. Barr E S & Co. raised its position in Zentalis Pharmaceuticals by 43.8% in the fourth quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock worth $78,000 after acquiring an additional 17,500 shares in the last quarter. Vanguard Group Inc. raised its position in Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after acquiring an additional 19,768 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at about $27,000.

Insider Buying and Selling

In other news, major shareholder Group Walters bought 6,459,973 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were purchased at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the acquisition, the insider directly owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. This trade represents a 91.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares of the company’s stock, valued at $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 46,617 shares of company stock worth $113,417 in the last quarter. Company insiders own 1.90% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.